Verseon is a technology-based drug discovery company founded in 2002. Our proprietary, computer-driven drug discovery platform uses computational chemistry, physics-based molecular modeling, and optimization embedded into a comprehensive in-house laboratory workflow to identify novel drug candidates faster and more inexpensively than conventional methods.
We use our platform to establish a diversified pipeline across multiple disease areas, and currently have drug programs in anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.
Verseon’s security token will be a form of a preferred share that grants its holder rights to a percentage of the company’s future drug program revenues. Initially, Verseon will offer its token in a private sale, followed by a public token sale.
Verseon is currently working with regulators on a prospectus for the token. Approval of the prospectus will make the security token available to investors in the UK and EU and investors in certain other jurisdictions where the company will seek additional approval from local regulators. The token will remain available to accredited investors, including those in the US.